Preventing the Progression of Multiple Sclerosis: Early Rehabilitative Treatment and Multimodal Assessment - Part B

Sponsor
Fondazione Don Carlo Gnocchi Onlus (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT06056960
Collaborator
IRCCS San Raffaele (Other), Azienda Sanitaria Locale di Cagliari (Other)
80
3
2
6.5
26.7
4.1

Study Details

Study Description

Brief Summary

It is widely recognized that physical exercise is safe and people with moderate Multiple Sclerosis (MS) are encouraged to train regularly to improve their skills in motor task execution. Several studies demonstrated that these activities represent an effective low-cost therapy which leads to significant and clinically meaningful improvements in gait and balance in people with MS (PwMS) with mild to moderate walking dysfunction, possibly also by promoting brain plasticity.

There is general agreement within the scientific community on the importance of timing intervention also during the early stages of MS to preserve or improve walking and balance abilities and fostering brain functional adaptation, thus slowing down the disease progression. Previous studies highlighted the need to early identify and manage gait disorders using a multimodal approach tailored on individual's need. Moreover, Functional Near-Infrared Spectroscopy (fNIRS) measures blood flow which accompanies neuronal activity and thus, it can provide spatial information about changes in cortical activation patterns due to the possible effects of exercise on cortical plasticity.

To the best of the investigators knowledge, no published studies have assessed the effect of exercise on mobility and brain activity in PwMS with minimal or clinically undetectable disability. This emphasizes the need of trials investigating the effect of walking exercise as preventive strategy on MS clinical worsening.

Condition or Disease Intervention/Treatment Phase
  • Other: Tailored Physical Activity
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Preventing the Progression of Physical Disability and Promoting Brain Functional Adaptation in People With Multiple Sclerosis: Integration of Early Rehabilitative Treatment and Multimodal Clinical and Instrumental Assessment - Part B
Anticipated Study Start Date :
Jul 15, 2024
Anticipated Primary Completion Date :
Jan 30, 2025
Anticipated Study Completion Date :
Jan 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Physical Activity

The experimental group will perform a combination of endurance and balance training tailored to the subject.

Other: Tailored Physical Activity
The intervention will comprise 16 sessions (2 sessions/week). 30 minutes of walking training wearing a heart rate (HR) monitor to keep exercise intensity below 70% of maximal HR. Right after, 30 minutes of balance exercises will be performed. An experienced physical therapist will tailor exercises. Subjects will be taught how to perform the exercises by themselves. A booklet will be provided to provide guidelines. A physical therapist will call subjects, every training day to check for any problem.

No Intervention: Usual Activity

The control group will perform their usual daily activities.

Outcome Measures

Primary Outcome Measures

  1. Fatigue Severity Scale (FSS) [Baseline, Post, FollowUp_6month]

    Is a 9-item self-administered questionnaire to measure the perceived impact of fatigue. The minimum score is 9 and maximum score possible is 63. Higher scores represent greater fatigue severity. If the score is calculated as the mean score of the 9 items, the cut-off score for the presence of the symptom fatigue is set as scores higher than 4.

Secondary Outcome Measures

  1. Differences in oxygenated hemoglobin (Delta oxyHb) [Baseline, Post, FollowUp_6month]

    The differences in oxyHb during task period and resting state. Data will be extracted from functional Near InfraRed Spectroscopy (fNIRS) assessment.

  2. Six Minute walking test (6MWT) [Baseline, Post, FollowUp_6month]

    Gait asymmetry and regularity extracted from Inertial Measurement Unit's during the six minute walking test.

  3. Number of steps/day [Baseline, Post, FollowUp_6month]

    Assessed by activity trackers, a non-invasive method of monitoring human rest/activity cycles. Subjects will be monitored for 1 week wearing an actigraph.

  4. Endurance walking capacity [Baseline, Post, FollowUp_6month]

    Assessed as the distance walked over 6 minutes as a sub-maximal test of endurance (6MWT).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age > 17 years

  • Stable disease course (without worsening over 1 point at the Expanded Disability Status Scale in the last 3 months)

Exclusion Criteria:
  • Major depression

  • Mini-Mental State Examination < 27

  • Other cardiovascular or orthopedic diseases that interfere with physical exercise

  • Progressive course of the disease

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ospedale Binaghi ASL Cagliari Cagliari Italy
2 IRCCS Ospedale San Raffele Milan Italy 20100
3 IRCCS Fondazione Don Carlo Gnocchi Milan Italy 20148

Sponsors and Collaborators

  • Fondazione Don Carlo Gnocchi Onlus
  • IRCCS San Raffaele
  • Azienda Sanitaria Locale di Cagliari

Investigators

  • Principal Investigator: Marco Rovaris, MD, IRCCS Fondazione Don Carlo Gnocchi
  • Principal Investigator: Raffaella Chieffo, MD, IRCCS Ospedale San Raffaele
  • Principal Investigator: Eleonora Cocco, MD, Ospedale Binaghi ASL Cagliari, Sardegna

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fondazione Don Carlo Gnocchi Onlus
ClinicalTrials.gov Identifier:
NCT06056960
Other Study ID Numbers:
  • 03_17/02/2021 Part B
First Posted:
Sep 28, 2023
Last Update Posted:
Sep 28, 2023
Last Verified:
Jul 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Fondazione Don Carlo Gnocchi Onlus
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 28, 2023